Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy

Condition: Prostatic Neoplasm

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT04234399

Sponsor: University of Vermont

Phase:

Eligibility:

• Age: minimum 40 Years maximum N/A
• Gender: Male

Inclusion Criteria:

1. Prostatectomy patients with previously undetectable PSA and subsequent biochemical recurrence defined by PSA between 0.2 ng/ml and 1.0 ng/ml within 4 weeks prior to Fluciclovine scan
2. Age >40
3. Ability to provide informed consent

Exclusion Criteria:

1. History of allergic reaction to Fluciclovine
2. Anti Androgen treatment in the 6 months prior to enrollment
3. Any patient whose body habitus, as determined by radiology personnel, will effectively inhibit the ability to obtain PET/CT imaging or will interfere with the images so as to make them clinically uninterpretable.

View trial on ClinicalTrials.gov